Abstract NY-BR-1 is a recently identiWed diVerentiation antigen of the mammary gland. To use NY-BR-1 for Tcell-based immunotherapy, analysis of its co-expression with HLA class I antigens is required. In the present tissue microarray study, primary breast cancers (n = 1,444), recurrences (n = 88), lymph node (n = 525) and distant metastases (n = 91) were studied for NY-BR-1 expression using a novel monoclonal antibody. NY-BR-1 expression was compared with prognosis, estrogen receptor, HER2-status, EGFR and HLA class I antigen expression. NY-BR-1 was more frequently expressed in grade 1 (82%) than in grade 2 (69%) and grade 3 (46%) carcinomas (P < 0.0001). Moreover, NY-BR-1 expression correlated directly with estrogen receptor expression (P < 0.0001) and inversely correlated with HER2-status and EGFR expression (P < 0.0001 for both). Considering high expression level of co-expression, 198/1,321 (15%) primary breast carcinomas and 4/65 (6%) distant metastases expressed NY-BR-1 and HLA class I, suggesting that active immunotherapy can be applied to about 10% of breast cancer patients. Survival analysis showed an association of NY-BR-1 expression with better patient outcome (P = 0.015). No diVerence between NY-BR-1 expression of primary tumors and metastases could be found, indicating that the presence of NY-BR-1 in metastases can be deduced from their corresponding primary. Forty-three paired biopsies taken from patients before and after chemotherapy suggest that NY-BR-1 expression is not inXuenced by preceding chemotherapy ( = 0.89, P < 0.0001). In summary, the co-expression of Jean-Philippe Theurillat and Ursina Zürrer-Härdi contributed equally to this study. 
Introduction
Targeted cancer drugs, e.g., trastuzumab against HER2 or geWtinib against EGFR, have been proven to be a novel eVective strategy for cancer treatment [1, 2] . T-cell-based immunotherapy targeting antigens such as cancer testis (CT) antigens or diVerentiation antigens is another promising new treatment modality, which is currently being tested in clinical trials [3] [4] [5] [6] [7] . Both targeted cancer drugs and Tcell-based immunotherapy display target speciWcity against cancer cells, thus reducing undesired eVects as encountered with conventional cancer chemotherapy. The expression of an optimal target for tumor immunotherapy should be restricted to or at least selective in malignant lesions. Examples are CT antigens or diVerentiation antigens that remain stable during disease progression [8] .
Recently, we have identiWed the NY-BR-1 gene by SEREX analysis (serological analysis of recombinant expression libraries) of a patient with metastatic breast carcinoma and we have shown that about 10% of the patients with NY-BR-1 positive tumors exhibited a humoral immune response to NY-BR-1 [8, 9] . In addition, others and we recently identiWed two HLA-A2 restricted epitopes that are recognized by CD8 positive T-cells [10, 11] . Both epitopes are naturally processed and presented. The NY-BR-1 gene is located on chromosome 10p11-p12 and is composed of 37 exons. It encodes a peptide of Mr 150,000-160,000, a putative transcription factor. Since its protein expression is restricted to normal and neoplastic breast epithelium, NY-BR-1 is classiWed as a diVerentiation antigen of the mammary gland. A recent immunohistochemical study with a limited number of breast carcinoma lesions has shown that NY-BR-1 is expressed in about 60% of breast carcinoma and has conWrmed the breast epithelium speciWcity [12] . Due to this organ-speciWcity, NY-BR-1 represents an attractive target for cancer immunotherapy and can be potentially used for diagnostic purposes in surgical pathology.
To explore NY-BR-1 as a potential target for cancer immunotherapy of breast cancer, more knowledge about the NY-BR-1 expression on a protein level in a larger cohort of primary tumors and distant metastases is paramount. Also, potential associations with clinical parameters and other markers such as estrogen receptor (ER) and progesterone receptor (PR) are necessary. Furthermore, for T-cell mediated immunization strategies, major histocompatibility complex (HLA) class I is required for presentation of target antigens, mediating the recognition of tumor cells by cytotoxic T-cells. Therefore, data about the presence of HLA class I and NY-BR-1 co-expression is crucial [13, 14] .
Consequently, in the present study we determined the protein expression of NY-BR-1 in a large number of primary breast carcinomas, lymph node and distant metastases by immunohistochemistry using tissue microarrays (TMA). NY-BR-1 expression was correlated with prognosis, predictive parameters, e.g., ER, epidermal growth factor receptor (EGFR) and HER2-gene ampliWcation as well as with HLA class I expression. Furthermore, we also analyzed the impact of chemotherapy on NY-BR-1 expression.
Materials and methods

Patients and tissues
Formalin-Wxed paraYn-embedded tissue samples from patients of the University Hospital Zurich between 1991 and 2005 were retrieved from the archives of the Institute of Surgical Pathology. This project was approved by the local Commission of Ethics (ref. no. StV 12-2005) . The mean age of the patients at diagnosis was 60.4 years (range 15-98). Twenty-Wve percent of the patients were pre-menopausal and 75% post-menopausal. H&E stained sections of all tumors were re-evaluated by one pathologist (J.P.T.) for suitability for TMA construction. The construction of TMA has been previously described [15] . The following tissues were arrayed into seven paraYn TMAs: 144 normal breast tissues, 148 carcinoma in situ lesions, 1,444 primary invasive carcinomas, 88 local recurrences, 525 lymph node metastases and 91 distant metastases. The primary carcinomas consisted of 1,135 (78.6%) invasive ductal and 217 (15.0%) invasive lobular carcinomas, according to the WHO tumor classiWcation. Other tumor types (6.4%) included invasive tubular, cribriforme, medullary, mucinous, apocrine, metaplastic, glycogen-rich clear cell, micropapillary and papillary carcinomas.
According to TNM criteria 706 tumors were pT1, 685 pT2, 105 pT3 and 150 pT4. A total of 414 tumors were pN0, 604 pN1 and 168 pN2/pN3. The pT-category and the pN-category could not be established for 12 and 427 cases, respectively. Histopathological grading was performed according to the modiWed Bloom and Richardson system [16] . Two hundred and four primary tumors were grade 1 (82%), 708 grade 2 (69%) and 490 grade 3 (46%).
Overall survival data from 1,091 patients were provided from the Cancer Register, Zurich. Additional data were obtained from the Department of Gynecology and the Department of Oncology of the University Hospital, Zurich.
To determine the impact of chemotherapy on NY-BR-1 expression, large paraYn sections from a previously described cohort of 43 patients were analyzed [17] . Tumor tissue before and 6 months after neoadjuvant chemotherapy was investigated for NY-BR-1 expression in each of these patients.
Immunohistochemistry
For initial analysis, immunostaining of monoclonal antibody (mAb) NY-BR-1 was adjusted to the Ventana Benchmark system by performing titrations and initial reactivity assessment in a small series of invasive breast cancer samples as previously described [12] .
ER and EGFR expression was detected using the Ventana Benchmark (Ventana Medical Systems, Tucson, AZ, USA) automated stainer according to the manufacturer's recommendations with mAbs 6F11 (Ventana) against estrogen receptor and mAbs 3C6 (Ventana) against EGFR.
For the analysis of HLA class I expression mAb HC-10 (1:100) was used, which recognizes a determinant expressed on virtually all ß2m-free HLA-B heavy chains and on ß2m-free HLA-A10, HLA-A28, HLA-A29, HLA-A30, HLA-A31, HLA-A32, and HLA-A33 heavy chains [18] .
TMAs were analyzed with the Ventana Benchmark automated staining system (Ventana) using Ventana reagents for the entire procedure. For antigen retrieval, slides were heated with cell conditioning solution (CC1) in a standard protocol. Endogenous peroxidase was blocked using the Ventana endogenous peroxidase blocking kit.
The immunohistochemical reactivity for all antibodies was measured as percentage of positive cells per spot (0, 5, 10, 20%, etc.), regardless of the intensity of staining. Apart from survival analysis and examination of NY-BR-1 expression before and after chemotherapy, all statistical procedures were based on percentage of positive cells per spot. For multivariate analysis, staining was categorized into positive (¸5% positive cells) and negative (<5% positive cells). For survival curves, kappa analysis and tables we used the following simpliWed scoring system for NY-BR-1: negative (0% positive cells), weak (1-70%), strong (>70%). ER and EGFR stains were considered as positive when at least 5% of the tumor cells or more were positive. The expression of HLA class I was scored in three groups: negative (0-25%), heterogeneous (26-75%) and positive (>75% positive tumor cells), as it has been recently described [19] .
The status of the HER2-neu proto-oncogene was assessed on TMAs by Xuorescence in situ hybridization (FISH) using direct Xuorescent-labeled DNA probes obtained from Pathvysion (VYSIS, Abott AG Diagnostic Division, Baar, Switzerland) and an Olympus microscope. The interpretation of the Xuorescence signals was carried out according to the manufacturer's recommendations. Presence of Wve or more HER2-neu copy number signals was deWned as ampliWcation.
Statistics
Categorical data were compared using chi-square test. The Spearman rank correlation was used to correlate continuous (NY-BR-1, ER, EGFR and HLA class I immunohistochemistry) as well as ordinal clinicopathological parameters (stage and grade). DiVerences of continuous parameters (NY-BR-1) between groups (menopausal and HER2-status) were analyzed using the Mann-Whitney test. To determine, expression diVerences within the same patient, Wilcoxon signed rank test was used. A measure of agreement ( analysis) was done to analyze the congruence of NY-BR-1 expression before and after neoadjuvant chemotherapy.
Overall survival was calculated using Kaplan-Meier curves with assessment of statistical signiWcance using logrank test. Univariate and stepwise (backwards) Cox proportional-hazard regression was used to determine hazard ratios and independent risk factors. Results were considered statistically signiWcant if P values were 0.05 or less. Figure 1 shows representative positive and negative immunohistochemical stainings for NY-BR-1, EGFR, ER and HLA class I. In our study we found NY-BR-1 expressed in 63.5% of all primary invasive carcinomas (Table 1) . NY-BR-1 was expressed in 80.7% of ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). The incidence of NY-BR-1 expression was signiWcantly higher in lobular lesions (LCIS 100%; invasive lobular cancer 73.8%, respectively) than in ductal lesions (DCIS 78.6%; invasive ductal cancer 61.1%, respectively; P = 0.0006). A heterogeneous weak to strong NY-BR-1 staining was observed in the epithelium of normal breast specimens, as described in our previous study [12] . A similar expression pattern was also present on all large tissue sections of lactating breast (n = 10). Table 2 gives a summary of the association of NY-BR-1 protein expression with established prognostic factors.
Results
NY-BR-1 protein expression in primary breast carcinoma lesions
DiVerences in number of cases among immunohistochemical markers were due to tissue damage (either tissue loss or inadequate tumor tissue) a problem associated with TMAs. NY-BR-1 protein expression was signiWcantly associated with tumor grade (P < 0.0001), but was not associated with tumor stage (pT-and pN-category) or bilaterality/multifocality (data not shown).
Apart from tumor grade, NY-BR-1 expression correlated signiWcantly with ER expression (P < 0.0001): 70.1% of the ER-positive tumors also co-expressed NY-BR-1, whereas over 66% of the ER-negative tumors were also negative for NY-BR-1.
NY-BR-1 expression inversely correlated to both HER2 ampliWcation and EGFR expression (P < 0.0001 each; Table 2 ), since NY-BR-1 was expressed in 65% of tumors without HER2 ampliWcation and in 67.4% of EGFR negative tumors.
Since HLA class I molecule expression on tumor cells is crucial for their recognition by T-cells, we screened the breast carcinoma lesions for NY-BR-1/HLA class I coexpression. Table 3 gives a summary of the association of NY-BR-1 protein expression and HLA class I expression. Among primary breast carcinomas, 587 out of 1,321 (44%) expressed at least heterogeneously HLA class I and weakly NY-BR-1. A similar expression level of both antigens was present in 163/470 (35%) lymph node metastases, 20/78 (25%) recurrences, and in 17/65 (26%) distant metastases. Corresponding strong expression levels of NY-BR-1 and HLA class I (both more than 70% of the tumor cells) was present in 198/1,321 (15%) primaries, 45/470 (10%) lymph node metastases, 3/78 (4%) recurrences, and in 4/65 (6%) distant metastases.
NY-BR-1 protein expression in recurrences and metastases
The NY-BR-1 expression in lymph node metastases (60.2%) was comparable to that in primary tumors (63.5%) but decreased to 52.2 and 49.4% in distant metastases and recurrences, respectively ( Table 1 Comparison of immunohistochemical reactivity of NY-BR-1 (as described in "Materials and methods") between primary tumors and lymph node metastasis (n = 406) revealed no statistical diVerences (P = 0.10). The immunohistochemical reactivity of NY-BR-1 was decreased in distant metastases (n = 36); this diVerence, however, did not reach the level of statistical signiWcance. In contrast, the immunohistochemical reactivity of NY-BR-1 was signiWcantly decreased in recurrences when compared to their primary counterparts (P = 0.019).
NY-BR-1 expression and patient prognosis
Preliminary data evaluated the quality of our survival data by correlating survival analyses with established prognostic factors. Low tumor grade, small tumor size, negative lymph node status, positive ER-status as well as negative EGFR and HER2-status were found to be highly signiWcant associated with improved clinical outcome in our patients (P < 0.0001, each; data partly shown in Fig. 2 and Table 4 ). Patients with strong NY-BR-1 expression had a better prognosis than patients with NY-BR-1 negative tumors (P = 0.008; data not shown). The 5-year overall survival for patients with strong expression was 83% compared to 74% for patients with NY-BR-1 negative tumors. Interestingly, when all patients were considered, those with weak NY-BR-1 expression in their tumors resembled those with strong NY-BR-1 expression in the favorable clinical course of the disease. However, when only pre-menopausal patients were considered, those with weak NY-BR-1 expression in their tumors resembled those with NY-BR-1 negative tumor in the poor outcome of the disease (Fig. 2 ). An additional analysis showed that this eVect was due to an increased number of high grade tumors with weak NY-BR-1 positivity in the pre-menopausal group.
Multivariate analysis conWrmed pT category, lymph node status, tumor grade and EGFR as well as HER2 genestatus to be independent prognostic markers ( Table 4) . NY-BR-1 expression and ER-status are both linked to grading and were therefore not independent prognostic variables. HLA class I expression was not associated with patient outcome in uni-and multivariate analyses.
EVect of chemotherapy on NY-BR-1 expression
To test whether chemotherapy could have an eVect on NY-BR-1 expression, we analyzed 43-paired biopsies taken from patients just before starting neoadjuvant chemotherapy and 6 months after having received neoadjuvant chemotherapy. Seventeen patients received anthracyclines, two taxane and seventeen anthracyclines combined with taxanes. The type of chemotherapy could not be determined for the remaining seven patients. NY-BR-1 expression by IHC in paired biopsies was categorized into negative, weakly and strongly positive (as described in "Materials and methods"). The staining pattern of the biopsies obtained before and after therapy was not diVerent in 40 (93%) of the 43 patients investigated ( = 0.89, P < 0.0001; 95% CI 81-99%). In this group, nine tumors were negative for NY-BR-1, 16 tumors expressed weakly and 15 strongly NY-BR-1. However, NY-BR-1 could not be detected in the biopsies obtained from two (4%) patients after chemotherapy with initially weakly and strongly positive tumors. The latter two patients had both received anthracycline-containing chemotherapies. Initial absence of NY-BR-1 expression was observed in one patient (2%), showing weak levels of NY-BR-1 in the tumor cells after chemotherapy. The type of chemotherapy could not be determined for this patient.
Discussion
In agreement with our recent immunohistochemical results obtained from 124 breast carcinoma lesions [12] , the present study of more than 2,000 breast carcinoma lesions with a recently developed mAb has shown that NY-BR-1 is a breast epithelium diVerentiation antigen. Its expression is associated with tumor diVerentiation, HER2-gene, EGFR and ER-status of breast cancer and prognosis. On large sections, we have observed that NY-BR-1 expression is heterogeneous in primary tumors [12] . Despite this intratumoral heterogeneity, the frequency of NY-BR-1 positive primary tumors on TMAs was comparable to that derived from large tissue section analysis. This indicates that the microarrray approach is suitable even when analyzing the expression of markers with a heterogeneous expression, because the large numbers of tumors compensate the small size of tissue samples [20, 21] . Due to its HLA class I coexpression and its stable expression in distant metastases NY-BR-1 appears to be a promising target for T-cell-based immunotherapy and vaccination strategies.
The present study has shown that multivariate analysis did not identify NY-BR-1 expression as an independent prognostic marker. In univariate analysis, strong NY-BR-1 expression is associated with a good prognosis due to the strong association of NY-BR-1 expression with tumor grade. Weak NY-BR-1 expression is associated with poor prognosis in pre-menopausal but not in postmenopausal patients. This Wnding can be explained by the larger number of high grade tumors in the group of pre-menopausal patients.
Like several other diVerentiation antigens, NY-BR-1 has a lower expression in metastatic lesions, because tumors of higher histological grade are more likely to metastasize. SpeciWcally NY-BR-1 expression decreases in the following order: carcinoma in situ (CIS) > invasive carcinoma > lymph node metastasis > distant metastasis. However, analysis of autologous primary and metastatic lesions of a particular patient showed a high concordance in NY-BR-1 expression in primary tumors and the corresponding lymph node metastases. Even distant metastases were found not to diVer signiWcantly from autologous primary tumors in NY-BR-1 expression level. Taken together, these results suggest that NY-BR-1 expression remains stable during disease progression. This Wnding is of particular interest, since therapeutic decisions in metastatic cancer are often based on the presence of biomarkers assessed solely in the primary tumor as it is almost always the case for the HER2-gene-status [17, 21, 22] .
Cancer immunotherapy is potentially applied as an additional therapeutic strategy in combination with conventional chemo-or endocrine therapy. Therefore, knowledge about the relation of NY-BR-1 to other established therapeutic target antigens is crucial. According to our data, NY-BR-1 is present in a large number of tumors without EGFR/ HER2 expression, suggesting that NY-BR-1 immunotherapy is a potential treatment option for patients with such tumors.
Breast cancer treatment largely depends on the hormone receptor status. Interestingly, NY-BR-1 expression was not associated to menopausal status, suggesting that estrogen levels might not inXuence NY-BR-1 expression to a large extent. However, the signiWcant reduction of NY-BR-1 expression in local recurrences, especially when only An increasing body of evidence suggests that modiWcation of the EGFR/HER2 signaling pathway by targeted cancer drugs oVers novel treatment options for breast cancer. Trastuzumab against HER2 has been shown to be eVective as an adjuvant therapy in combination with chemotherapy [1, 2] . Recent clinical observations suggested that EGFRsignaling-inhibitors might restore anti-estrogene-sensitivity after tamoxifen-acquired resistance [23, 24] . Our previous study comprising a limited number of breast cancer lesions (n = 124) revealed a weak linear correlation between NY-BR-1 expression and HER2-amplication [12] . Sixty-nine percent of the primary breast cancer coexpressed NY-BR-1. In contrast, in the present study we found an inverse correlation between HER2/EGFR expression and NY-BR-1. This discrepancy is due to the fact that the former study included a much higher percentage of poorly diVerentiated, HER2-ampliWed tumors (percentage of HER2-ampliWcation 57 vs. 14%). The much higher number of tumors and a prevalence of HER2-ampliWcation, which is comparable to the literature [25] indicate that the present results are more informative. Despite a weak inverse correlation, we found in the present study a coexpression of NY-BR-1 in about 50% of HER2-ampliWed as well as in EGFR positive carcinomas. Therefore, active speciWc immunotherapy targeting NY-BR-1 could be theoretically considered in combination to other targeted cancer drugs as an early, possibly adjuvant treatment option.
Currently, active speciWc immunotherapy is mostly applied in patients with metastatic disease, who have already received chemotherapy in an adjuvant or rarely in a neoadjuvant setting. Therefore it is important to know whether chemotherapy could inXuence NY-BR-1 expression. Our data indicate that neoadjuvant chemotherapy may have no eVect on NY-BR-1 expression, suggesting that active speciWc immunotherapy targeting NY-BR-1 can be considered even in patients who have been treated with several chemotherapy cycles.
Successful implementation of T-cell-based immunotherapy of malignant diseases requires that HLA class I antigens are expressed on tumor cells and that they present tumor antigen derived peptides HLA class I antigen restricted, tumor antigen-speciWc cytotoxic T-cells [13, 14] . However, abnormalities in HLA class I antigen expression and/or function and/or in antigen-processing machinery are frequently found in human malignancies [26, 27] . Therefore knowledge about NY-BR-1 and HLA class I antigen co-expression are crucial, if T-cell based immunotherapy targeting NY-BR-1 is considered. In 15% of primary breast carcinoma, a strong coexpression of both antigens was observed. Although this frequency of HLA class I/NY-BR-1 co-expression in primary tumors is promising for T-cell-based immunotherapy, clinical trials will be primarily implemented in patients with metastatic disease. In distant metastases, NY-BR-1 and HLA class I was co-expressed to some extent in 26% of the cases-however, we observed only in 6% a strong co-expression of both antigens. The decreased level of coexpression was mainly due to a decrease of HLA class I expression observed during metastatic spread. Surprisingly, uni-and multivariate analysis did not show an association of HLA class I expression with prognosis in our patient cohort. This Wnding is in contrast to Wndings of Madjd et al. [28] recent results. The latter investigators identiWed HLA class I antigen loss as an independent marker of good prognosis. The discrepancy between Madjd et al. results and our own are not likely to reXect diVerences in the methodology used since in both studies TMA and mAb HC10 were utilized. A more likely explanation for the conXicting results is represented by diVerences in the characteristics of the patient populations investigated in the two studies.
In summary, we have demonstrated that NY-BR-1 meets most, if not all the criteria required to be utilized as a target for T-cell-based immunotherapy. 
